Stock Ratings / Health Care / EDSA / news

NNVC (33) NSRX (36) LITS (42) VERU (43) ⌘ Pro Terminal →

Why EDSA Stock surged +5.47% Today — RQD Quant Desk Flash

$2.70 +5.47% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Edesa Biotech Inc. (EDSA) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $36.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EDSA)Realized 20D OHLCV Swing Band: ±12.5%

AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why EDSA Stock surged +5.47% Today — RQD Quant Desk Flash

Edesa Biotech Inc. (EDSA) surged +5.47% to $2.70, trading at 10% of its 52-week range ($0.72 – $20.32). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

▸Technical Tape: Trading at 10% of its 52-week range ($0.72 – $20.32) with RSI-14 at 32.8 (NEUTRAL RANGE).
▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.70 (no active unusual options sweep snapshot on file).
▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.

Live EDSA Headlines & Catalysts

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EDSA)

✓Walkthrough of EDSA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EDSA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -85.23%▲ RESISTANCE BREAKOUT

2026-10-30O $2.86H $2.86L $2.55C $2.70VOL 30.6K

RES: $2.68SUP: $2.40SMA50: $3.78SMA200: $5.66

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EDSA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EDSA Butterfly Map → + Track EDSA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EDSA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EDSA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EDSA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EDSA)

Health Care Rank #588 of 1016 ⚔️ NNVC vs EDSA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EDSA vs. NNVC, NSRX, LITS, VERU)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Edesa Biotech Inc. (EDSA) ranks #588 by composite RQD confidence (42/100, grade D-) and #785 by equity capitalization ($36.5M). Within this direct 5-issuer industry benchmark cohort, EDSA leads on earnings valuation at N/A trailing P/E, while LITS leads on capital efficiency and profitability with -18.9% ROIC and — gross margin. VERU currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with EDSA at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EDSA ACTIVE Edesa Biotech Inc.	D-	42/100	—	—	-35.0%	+5.47%	$36.5M	Benchmark Subject
NNVC NanoViricides Inc.	E	33/100	—	—	-35.0%	-1.38%	$36.5M	/nnvc-vs-edsa →
NSRX Nasus Pharma Ltd.	D-	36/100	—	—	-35.0%	-4.49%	$37.4M	/nsrx-vs-edsa →
LITS Lite Strategy Inc.	D-	42/100	—	—	-18.9%	-4.88%	$35.6M	/lits-vs-edsa →
VERU Veru Inc.	D-	43/100	—	—	-35.0%	-1.76%	$38.0M	/veru-vs-edsa →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001540159

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Edesa Biotech Inc. (EDSA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$7.2M, operating cash flow of -$7.3M, and free cash flow of -$7.3M (-49.7% YoY). On the balance sheet, EDSA closed FY2025 with $14.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$0	-$7.2M	-$7.3M	-$7.3M	$14.7M	—
FY2024 (FY)	2024-09-30	$0	-$6.2M	-$4.9M	-$4.9M	$4.2M	—
FY2023 (FY)	2023-09-30	$0	-$8.4M	-$6.6M	-$6.6M	—	—

3. EDSA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EDSA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Edesa Biotech Inc. (NASDAQ: EDSA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $2.70 (+5.47% 1D, market cap $36.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EDSA ranks #588 in composite RQD confidence.

How does EDSA compare to NNVC and NSRX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EDSA carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NNVC (NanoViricides Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $36.5M) and NSRX (Nasus Pharma Ltd.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $37.4M). Among the 5-stock peer group, EDSA leads on earnings multiple (N/A) while LITS leads on capital efficiency (-18.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EDSA?

Per EDSA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001540159), Edesa Biotech Inc. generated $0 in revenue, -$7.2M in net income, and -$7.3M in free cash flow against $14.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EDSA trading relative to its 50-day, 200-day, and 52-week technical levels?

EDSA last traded at $2.70 (+5.47% on volume of 44,353 shares), positioning the stock -28.57% below its 50-day simple moving average ($3.78) and -52.30% below its 200-day simple moving average ($5.66). Across its 52-week range of $0.72 to $20.32, EDSA sits at the 10.1% percentile with a 14-day RSI of 32.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.36 to $3.04).

EDSA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Why is EDSA stock moving today?

Why EDSA Stock surged +5.47% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

Direct Sub-Reports: EDSA RQD Cockpit EDSA 12M Forecast EDSA Earnings & Move EDSA Dividends & DRIP EDSA Insiders & 13F EDSA Whale Options EDSA Profit Sankey EDSA News & Why